glp-1 advantage book The Handbook by Ian Marber The GLP-1 Advantage Beyond the

2025: Novo Nordisk announced positive Phase 3 ESSENCE trial results for semaglutide in early Alzheimer's disease, reporting statistically significant slowing of cognitive and functional decline a breakthrough data package that could establish GLP-1 therapy as a neuroprotective agent and open an addressable market of 6.5 million Alzheimer's patients in the U.S

This is a study average, not a prediction of your personal result

Questions about medication selection: Which specific GLP-1 medication do you recommend for me, and why

The medications are a revolutionary treatment for Type 2 diabetes and obesity, experts say, but like most drugs, they come with side effects, with nausea being one of the most common reported for people taking Ozempic

Medications are filled by state-licensed pharmacies

When blood glucose remains persistently high, as it does in poorly managed diabetes, it causes microvascular damage throughout the body